Tadalafil tablets recalled for manufacturing quality control deviations
Accord Healthcare is recalling Tadalafil 10 mg tablets in the United States, Puerto Rico, and Canada due to manufacturing quality control deviations discovered during an FDA inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall based on manufacturing quality control deviations discovered during inspection. No adverse events have been reported, but CGMP deviations represent potential risk to product integrity in a prescription medication.
Plain-English summary
Accord Healthcare, Inc., is recalling Tadalafil tablets, 10 mg strength, in both 30-count and 500-count bottles. The recall affects approximately 176,323 bottles distributed throughout the United States, Puerto Rico, and Canada.
The recall was initiated following an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations in the manufacturing process. This is classified as a Class II recall.
Consumers should not discard their medication without consulting their healthcare provider. Affected lot numbers and expiration dates are available in the full FDA recall notice. Consumers with questions should contact their healthcare provider or pharmacist for guidance on obtaining replacement medication.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Oral Tablet
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2002525
- Exp. Date 4/30/2023
- P2004442
- Exp. Date 7/31/2023
- P2005014
- Exp. Date 8/31/2023
- P2005015
- P2005016
- P2005825
- Exp. Date 10/31/2023
- P2005824
- P2005826
- P2100368
- Exp. Date 12/31/2023
- P2100444
- P2101262
- Exp. Date 2/29/2024
- P2101263
- P2200813
- Exp. Date 1/31/2025
UPCs (5)
- 0316729372107
- 0316729369107
- 0316729370103
- 316729371100
- 316729371162
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · TADALAFIL
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- ModerateTadalafil tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27